Global clinical development achievements
- Receipt of the U.S. Phase 2a clinical study report (CSR) for CU06 (Rivasterat) in diabetic macular edema (2024.04).
TECHNOLOGY PLATFORMS
Building on its expertise in vascular disease research, Curacle develops small-molecule drugs and antibody therapeutics tailored to the characteristics of each disease and its therapeutic goals. Through its proprietary SOLVADYS® platform and collaborative research using MabTics’ EAGLES® platform, Curacle discovers competitive drug candidates and advances clinical development and global out-licensing.
CURACLE PROPRIETARY PLATFORM
SOLVADYS® recreates disease-relevant conditions in human endothelial cells to identify compounds that improve impaired function.
Compounds are designed and refined using multiple readouts, including barrier function and inflammatory responses. Efficacy and mechanism studies in disease models, together with pharmacokinetic assessments, guide candidate selection.

MABTICS PLATFORM · CO-DEVELOPMENT WITH CURACLE
EAGLES® is MabTics’ platform for identifying antibodies from diverse libraries and engineering their function and structure for therapeutic applications.
Curacle and MabTics combine vascular disease expertise with antibody technologies to co-develop candidates that activate protective vascular signals or inhibit disease-driving signals.

Library diversity exceeding 2.5 × 10¹¹ supports antibody discovery across multiple targets.
Evaluation goes beyond target binding to assess functions such as signal activation and inhibition.
Combines mechanisms and optimizes antibody structure and function.